PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
d to a collection of information unless it contains a valid OMB control purples.

		f information unless it contains a valid OMB control number.	
Substitute for form 1449A-B/PTO	Complete if Known		
.,	Application Number	10/672,302	
INFORMATION DISCLOSOFIES STATEMENT BY APPLICANT	Filing Date	September 26, 2003	
STATEMENT BY APP(ICANT CA	First Named Inventor	Hong Jin	
STATEMENT BY APPLICANT	Group Art Unit	1648	
200 0 0 0000	Examiner Name	Unassigned	
(use as many sheets a helessary)	Attorney Docket Number	26-000320US	
	Date Submitted	January 27, 2004	
They to the			

		U.	S. PATENT DOCUMENTS		
	U.S. Patent Document		Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,
Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal
01	5,922,326		Murphy et al.	07-13-1999	
					•
_		Cite Number No.	Cite Number Kind Code (if known)	Cite Number Kind Code (if known) Name of Patentee or Applicant of Cited Document	Cite Number Kind Code (if known)  Name of Patentee or Applicant of Cited Document MM-DD-YYYY  Name of Patentee or Applicant of Cited Document MM-DD-YYYYY

				FOREIGI	N PATENT DOCUMENT	TS		
		Foreign Patent Document			Date of Publication	Pages, Columns, Lines,	Π	
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Ľ
BB	02	wo -	02/44334	A2	Aviron, Inc.	06-06-2002		
				1				1

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Initials No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
BB	03	Ahmadian et al. (1999) Detection and characterization of proteins encoded by the second ORF of the M2 gene of pneumoviruses. J Gen Virol., 80:2011-2016.	
	04	Ahmadian et al. (2000) Expression of the ORF-2 protein of the human respiratory syncytial M2 gene is initiated by a ribosomal termination-dependent reinitiation mechanism. EMBO J., 19:2681-2689.	
	05	Anderson et al. (1985) Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J Clin Microbiol., 22:1050-1052.	
	06	Asenjo et al. (2000) Regulated but not constitutive human respiratory syncytial virus (HRSV) P protein phosphorylation is essential for oligomerization. FEBS Lett 467:279-284	
	07	Barik et al. (1995) Phosphorylation of Ser <sup>232</sup> Directly Regulates the Transcriptional Activity of the P Protein of Human Respiratory Syncytial Virus: Phosphorylation of Ser <sup>237</sup> May Play an Accessory Role. Virology 213:405-412	
	08	Bermingham et al. (1999) The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A, 96:11259-11264.	
BB	09	Bukreyev et al. (1996) Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. J Virol, 70:6634-6641.	

Examiner /Benjamin Blumel/	Date Considered	11/30/2006
----------------------------	--------------------	------------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is In conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)

Approved for use through 04/30/2003, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Under the P

**Application Number** 10/672,302 September 26, 2003 Filing Date First Named Inventor **Hong Jin Group Art Unit** 1648 **Examiner Name** Unassigned

**Attorney Docket Number** 26-000320US January 27, 2004 **Date Submitted** 

(use as many sheets as necessary)

ВВ	10	Caravokyri et al. (1992) Assignment of mutant tsN1 respiratory syncytial virus to the P protein gene. J. G						
	11	Cheng et al. (2001) Chimeric Subgroup A Respirato Substituted by Those of Subgroup B and RSV witho African Green Monkeys. Virology 283:59-68	ory Syncytial Virus	with the Glycoproteins				
	12	Cheng et al. (2002) Expression of ß-galactosidase l viruses for microneutralization assay. J Virol Method		spiratory syncytial				
	13	Collins et al. (1985) The envelope-associated 22K virus: nucleotide sequence of the mRNA and a relative						
	14	Collins et al. (1995) Production of infectious human respiratory syncytial virus from cloned cDNA confirms and essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. 92:11563-11567						
15		Dupuy et al. (1999) Casein Kinase 2-Mediated Phosphorylation of Respiratory Synctial Virus Phosphoprotein P is Essential for the Transcription Elongation Activity of the Viral Polymerase; Phosphorylation by Casein Kinase 1 Occurs Mainly at Ser <sup>215</sup> and is without Effect. J. Virol. 73:8384-8392						
	16	Faulkner et al. (1976) Respiratory Syncytial Virus ts Mutants and Nuclear Immunofluorescence. J. Virol. 20:487-500						
	17	Garcia-Barreno et al. (1996) Identification of Protein Regions Involved in the Interaction of Human Respiratory Syncytial Virus Phosphoprotein and Nucleoprtein: Significance for Nucleocapsid Assembly and Formation of Cytoplasmic Inclusions. J. Virol. 70:801-808						
	18	Hardy et al. (1998) The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. J Virol. 72: 520-526.						
19		Hardy et al. (1999) Diverse Gene Functions of Respiratory Syncytial Virus Modulate the Efficiency of Transcription Termination and Respond Differently to M2-Mediated Antitermination. J Virol. 73: 170-176.						
		Hardy et al. (2000) The Cys <sub>3</sub> -His <sub>1</sub> Motif of the Respiratory Syncytial Virus M2-1 Protein is Essential for Protein Function. J. Virol. 74: 5880-5885.						
	21	Jin et al. (1998) Recombinant Human Respiratory Syncytial Virus (RSV) from cDNA and Construction Subgroup A and B Chimeric RSV. Virology 251:206-214						
	22	Jin et al. (2000) Recombinant Respiratory Syncytial Viruses with Deletions in the NS1, NS2, SH, and M2-2 Genes are Attenuated <i>in Vitro</i> and <i>in Vivo</i> . Virology 273:210-218						
ВВ	23	Jin et al. (2000) Respiratory Syncytial Virus that Lac Gene (m2-2) Has Altered Growth Characteristics an 82						
Examine Signatur		/Benjamin Blumel/	Date Considered	11/30/2006				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. Under the Pap no persons are required

Substitute for fold 3449A-B/PT INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

C	omplete if Known
Application Number	10/672,302
Filing Date	September 26, 2003
First Named Inventor	Hong Jin
Group Art Unit	1648
Examiner Name	Unassigned
Attorney Docket Number	26-000320US
Date Submitted	January 27, 2004

ВВ	24	Jin et al. (2003) Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 21:3647-3652	
	25	Khattar et al. (2001) Mapping the domains on the phosphoprotein of bovine respiratory syncytial virus required for N-P and P-L interactions using a minigenome system. J. Gen Virol. 82:775-779	
	26	Lu et al. (2002) Identification of Temperature-Senstive Mutations in the Phosphoprotein of Respiratory Syncytial Virus that are Likely Involved in its Interaction with the Nucleoprotein. J. Virol. 76:2871-2880	
	27	Lu et al. (2002) The major phosphorylation sites of the respiratory syncytial virus phosphoprotein are dispensable for virus replication in vitro. J Virol. 76:10776-10784.	
	28	Mallipeddi et al. (1996) Mapping the domains on the phosphoprotein of bovine respiratory syncytial virus required for N-P interaction using a two-hybrid system. J. Gen Virol. 77:1019-1023	
	29	Marriott et al. (1999) A single Amino Acid Substitution in the Phosphoprotein of Respiratory Syncytial Virus Confers Thermosensivity in a Reconstituted RNA Polymerase System. J. Virol. 73:5162-5165	
	30	Slack et al. (1998) Characterization of the interaction of the human respiratory syncytial virus phosphoprotein and nucleocapsid protein using the two-hybrid system. Virus Research 55:167-176	
	31	Tang et al. (2001) Requirement of Cysteines and Length of the Human Respiratory Syncytial Virus M2-1 Protein for Protein Function and Virus Viability. J. Virol. 75:11328-11335	
	32	<b>Techaarpornkul</b> et al. (2001) Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol, 75:6825-6834.	
	33	Teng et al. (2000) Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol, 74:9317-9321.	
	34	Whitehead et al. (1998) A Single Nucleotide Substitution in the Transcription Start Signal of the M2 Gene of Respiratory Syncytial Virus Vaccine Candidate <i>cpts</i> 248/404 is the Major Determinant of the Temperature-Senstitive and Attenuation Phenogypes. Virology 247:232-239	
ВВ	35	Zhou et al. (2003) Identification of amino acids that are critical to the processivity function of respiratory syncytial virus M2-1 protein. J Virol, 77:5046-5053.	

	<del></del>		
Examiner		l Date	
Signatura	/Benjamin Blumel/	Considered	11/30/2006
Signature	, 2011 Julii 22 uli 02 /	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number

	Order the Paperwork Reduction Act of 1995, no persons an		<del></del>
	Substitute for form 1449A-B/PTO		omplete if Known
		Application Number	10/672,302
1P	F NFORMATION DISCLOSURE	Filing Date	September 26, 2003
0,	***ATEMENT BY APPLICANT	First Named Inventor	Hong Jin
	and E	Group Art Unit	1648
APR 1	2004	Examiner Name	Unassigned
	(use as many sheets as necessary)	Attorney Docket Number	26-000320US
(h)	A. J.	Date Submitted	April 13, 2004
V/ A			

			U.	S. PATENT DOCUMENTS		
Examiner Initials	Cite No.	U.S. Patent De Number	ocument Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
BB	01	6,713,066	B1	Collins et al.	03-30-2004	
				,	1	
				<del> </del>	· · · · · · · · · · · · · · · · · · ·	

		Fo	reign Patent Docu		N PATENT DOCUMEN'	Date of Publication	Pages, Columns, Lines,	<del></del>
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Ľ
								L
·	·			-				L
			<u>-</u>					L
	-,		<del></del>					H
·····				-				H

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		·				
			1			
			1			

Examiner		Date	
- Maiiiii 101		Date	11/20/0000
Signature	/Benjamin Blumel/	0	11/30/2006
Signature	, benjamin bramer,	Considered	,,
		000.00	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.